Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.

Cell death & disease - 21 Aug 2020

Wiese Maria, Hamdan Feda H, Kubiak Klaudia, Diederichs Christopher, Gielen Gerrit H, Nussbaumer Gunther, Carcaboso Angel M, Hulleman Esther, Johnsen Steven A, Kramm Christof M

Abstract excerpt

Diffuse intrinsic pontine gliomas (DIPG) are the most aggressive brain tumors in children with 5-year survival rates of only 2%. About 85% of all DIPG are characterized by a lysine-to-methionine substitution in histone 3, which leads to global H3K27 hypomethylation accompanied by H3K27 hyperacetylation. Hyperacetylation in DIPG favors the action of the Bromodomain and Extra-Terminal (BET) protein BRD4, and leads...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Azepines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Stem Neoplasms

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to CREB-Binding Protein

Share to Nucleosomes

Share to Pyrimidinones

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 32826850
DOI: 10.1038/s41419-020-02800-7
PMCID: PMC7442654

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.PMID 32826850Read ↗

Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.Semantic proximity Read ↗

Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.Semantic proximity Read ↗

Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targetsSemantic proximity Read ↗

Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG.Semantic proximity Read ↗

Targeting the SP/KLF Transcriptional Regulatory Network Synergizes with HDAC Inhibition to Impede Progression of H3K27M Diffuse Intrinsic Pontine Glioma.Semantic proximity Read ↗

Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPGSemantic proximity Read ↗

Super elongation complex as a targetable dependency in diffuse midline gliomaSemantic proximity Read ↗

Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.Semantic proximity Read ↗

Therapeutic reversal of prenatal pontine ID1 signaling in DIPGSemantic proximity Read ↗

Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement.Semantic proximity Read ↗

Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine gliomaSemantic proximity Read ↗

Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.